Preview

Вопросы современной педиатрии

Расширенный поиск

ГЕМОФАГОЦИТАРНЫЙ ЛИМФОГИСТИОЦИТОЗ

Аннотация

Гемофагоцитарный лимфогистиоцитоз – редкое и зачастую фатальное расстройство регуляции иммунного ответа, в основе патогенеза которого лежат дефекты клеточной цитотоксичности и гиперпродукция провоспалительных цитокинов. Различают генетически детерминированные формы гемофагоцитарного лимфогистиоцитоза и вторичные гемофагоцитарные синдромы, ассоциированные с инфекциями, злокачественными новообразованиями, аутоиммунными заболеваниями и иммунодефицитами. В статье дается краткое описание патогенеза, клинических проявлений и подходов к терапии гемофагоцитарных синдромов.
Ключевые слова: гемофагоцитарный лимфогистиоцитоз, иммуносупрессия, циклоспорин А, этопозид, дексаметазон.
(Вопросы современной педиатрии. 2009; 8(3):66-75)

Об авторах

М.А. Масчан
Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии МЗ РФ Российская детская клиническая больница Росздрава
Россия


Г.А. Новичкова
Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии МЗ РФ
Россия


Список литературы

1. Favara B.E. Hemophagocytic lymphohistiocytosis: a hemophagocytic syndrome. Semin.Diagn.Pathol. 1992; 9 (1): 63–74.

2. Новичкова Г.А., Минков М., Масчан М.А., Чернов В.М. Гистиоцитозы в кн. Клиническая онкогематология. Под ред. М.А.Волковой. М. 2007.

3. Arceci R.J. When T cells and macrophages do not talk: the hemophagocytic syndromes. Curr.Opin.Hematol. 2008; 15 (4): 359–367.

4. Farquhar J.W., Claireaux A. E. Familial haemophagocytic reticulosis. Arch.Dis.Child. 1952; 27 (136): 519–525.

5. Filipovich A.H. Hemophagocytic lymphohistiocytosis: a lethal disorder of immune regulation. J.Pediatr. 1997; 130 (3): 337–338.

6. Henter J.I. Biology and treatment of familial hemophagocytic lymphohistiocytosis: importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis. Med.Pediatr.Oncol. 2002; 38 (5): 305–309.

7. Voskoboinik I., Smyth M.J., Trapani J.A. Perforin-mediated target-cell death and immune homeostasis. Nat.Rev.Immunol. 2006; 6 (12): 940–952.

8. Henter J.I., Elinder G., Soder, O. et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991; 78 (11): 2918–2922.

9. Osugi Y. Hara J., Tagawa S. et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 1997; 89 (11): 4100–4103.

10. JordanM., Filipovich A.H. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single (big) step. Bone Marrow Transplant. 2008; 42 (7): 433–437.

11. Dufourcq-Lagelouse R., Jabado N., Deist F.et al. Linkage of familial hemophagocytic lymphohistiocytosis to 10q21-22 and evidence for heterogeneity. Am. J. Hum. Genet. 1999; 64 (1): 172–179.

12. Ohadi M., Lalloz M.R., Sham P. et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. Am. J. Hum. Genet. 1999; 64 (1): 165–171.

13. Stepp S.E., Dufourcq–Lagelouse R., Deist F. et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science.1999; 286 (5446): 1957–1959.

14. Stadt U., Schmidt S., Kasper B. et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type 4 to chromosome 6q24 and identification of mutations in syntaxin 1. Hum.Mol.Genet. 2005; 14 (6): 827–834.

15. Feldmann J., Callebaut I., Raposo G. et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003; 115 (4): 461–473.

16. Henter J.I., Elinder G., Soder O. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr.Scand. 1991; 80 (4): 428–435.

17. Arico M., Janka G., Fischer A.et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia. 1996; 10 (2): 197–203.

18. Janka G. E. Familial hemophagocytic lymphohistiocytosis. Eur. J. Pediatr. 1983; 140 (3): 221–230.

19. Haddad E., Sulis M.L., Jabado N. et al. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood. 1997; 89 (3): 794–800.

20. Henter J. I., Elinder G., Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin. Oncol. 1991; 18 (1): 29–33.

21. Egeler R.M., Shapiro R., Loechelt B. Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis. J.Pediatr.Hematol.Oncol.1996; 18 (4): 340–345.

22. Kogawa K., Lee S. M., Villanueva J. et al. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002; 99 (1): 61–66.

23. Marcenaro S., Gallo F., Martini S. et al. Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13–4 defect and discriminates between genetic subtypes of the disease. Blood. 2006; 108 (7): 2316–2323.

24. Nezelof C. Hemophagocytic lymphohistiocytosis as a syndrome: correlation of clinicopathological data. Pediatr .Hematol. Oncol. 1989; 6 (3): 207–211.

25. Henter J.I. Nennesmo, I. Neuropathologic findings and neurologic symptoms in twenty-three children with hemophagocytic lymphohistiocytosis. J. Pediatr.1997; 130 (3): 358–365.

26. Henter J.I., Horne A., Arico M. et al. HLH–2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer. 2007; 48 (2): 124–131.

27. Imashuku S. Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. Int. J. Hematol. 1997; 66 (2): 135–151.

28. Henter J.I., Arico M., Egeler R.M. et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med. Pediatr. Oncol. 1997; 28 (5): 342–347.

29. Henter J.I., Samuelsson–Horne A., Aric M. et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002; 100 (7): 2367–2373.

30. Mahlaoui N., Ouachee-Chardin M. et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with anti–thymocyte globulins: a single center retrospective report of 38 patients. Pediatrics. 2007; 120 (3): 622–628.

31. Adachi S., Kubota M., Akiyama Y. et al. Successful bone marrow transplantation from an HLA-identical unrelated donor in a patient with hemophagocytic lymphohistiocytosis. Bone Marrow Transplant.1997; 19 (2): 183–185.

32. Baker K.S., Delaat C.A., Steinbuch M. et al. Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation. Blood.1997; 89 (10): 3857–3863.

33. Jabado N., de Graeff–Meeder E.R., Cavazzana-Calvo M. et al. Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors. Blood. 1997; 90 (12): 4743–4748.

34. Ouachee-Chardin M., Elie C. et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single center report of 48 patients. Pediatrics. 2006; 117 (4): 743–750.

35. Cooper N., Rao K., Gilmour K. et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood. 2006; 107 (3): 1233–1236.

36. Janka G., Imashuku S., Elinder G. et al. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol. Oncol. Clin. North Am.1998; 12 (2): 435–444.

37. Risdall R.J., McKenna R.W., Nesbit M.E. et al. Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer.1979; 44 (3): 993–1002.

38. Fisman D.N. Hemophagocytic syndromes and infection. Emerg. Infect. Dis. 2000; 6 (6): 601–608.

39. Asci G., Toz H., Ozkahya M. et al. High dose immunoglobulin therapy in renal transplant recipients with hemophagocytic histiocytic syndrome. J. Nephrol. 2006; 19 (3): 322–326.

40. Kasahara Y., Yachie A., Takei K. et al. Differential cellular targets of Epstein–Barr virus (EBV) infection between acute EBV–associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood. 2001; 98 (6): 1882–1888.

41. Kasahara Y., Yachie A. Cell type specific infection of Epstein-Barr virus (EBV) in EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Crit. Rev. Oncol. Hematol. 2002; 44 (3): 283–294.

42. Kawaguchi H., Miyashita T., Herbst H. et al. Epstein–Barr virus-infected T lymphocytes in Epstein–Barr virus–associated hemophagocytic syndrome. J. Clin. Invest. 1993; 92 (3): 1444–1450.

43. Imashuku S., Hibi S., Ohara T. et al. Effective control of Epstein-Barr virus related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood. 1999; 93 (6): 1869–1874.

44. Imashuku S., Kuriyama K., Teramura T. et al. Requirement for etoposide in the treatment of Epstein–Barr virus–associated hemophagocytic lymphohistiocytosis. J. Clin. Oncol. 2001; 19 (10): 2665–2673.

45. Myers T.J., Kessimian N., Schwartz S. Mediastinal germ cell tumor associated with the hemophagocytic syndrome. Ann .Intern. Med. 1988; 109 (6): 504–505.

46. Nakamoto T., Ogawa S., Mano H. et al. Hemophagocytic syndrome associated with non-Hodgkin's lymphoma of B–cell type. Am. J. Hematol. 1994; 47 (4): 335–336.

47. Okada Y., Nakanishi I., Nomura H. et al. Angiotropic B-cell lymphoma with hemophagocytic syndrome. Pathol. Res. Pract. 1994; 190 (7): 718–724.

48. Takahashi N., Miura I., Chubachi A. et al. A clinicopathological study of 20 patients with T/natural killer (NK)–cell lymphoma associated hemophagocytic syndrome with special reference to nasal and nasal type NK/T-cell lymphoma. Int. J. Hematol. 2001; 74 (3): 303–308.

49. Chin M., Mugishima H., Takamura M. et al. Hemophagocytic syndrome and hepatosplenic gammadelta T–cell lymphoma with isochromosome 7q and 8 trisomy. J. Pediatr. Hematol. Oncol. 2004; 26 (6): 375–378.

50. Shimazaki C., Inaba T., Nakagawa M. B-cell lymphoma-associated hemophagocytic syndrome. Leuk. Lymphoma.2000; 38 (1–2): 121–130.

51. Grom A.A. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr. Opin.Rheumatol. 2003; 15 (5): 587–590.

52. Morris J.A., Adamson A.R., Holt P.J. Still's disease and the virus-associated haemophagocytic syndrome. Ann. Rheum. Dis. 1985; 44 (5): 349–353.

53. Prieur A.M., Fischer A. Griscelli C. Still's disease and haemophagocytic syndrome. Ann. Rheum. Dis. 1985; 44 (11): 806.

54. Cortis E., Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr.Suppl. 2006; 95 (452): 38–41.

55. Grom A.A. Natural killer cell dysfunction: A common pathway in systemic onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum.2004; 50 (3): 689–698.


Рецензия

Для цитирования:


Масчан М., Новичкова Г. ГЕМОФАГОЦИТАРНЫЙ ЛИМФОГИСТИОЦИТОЗ. Вопросы современной педиатрии. 2009;8(3):66-75.

For citation:


Maschan M., Novichkova G. HEMOPHAGOCYTAL LYMPHOHISTIOCYTOSIS. Current Pediatrics. 2009;8(3):66-75.

Просмотров: 687


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution-NonCommercial 4.0 International.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)